General

In Brief: FDA Approves New Drug to Improve Sexual Desire in Women

The Food and Drug Administration (FDA) has approved a new drug for the treatment of hypoactive sexual desire disorder in premenopausal women.  Bremelanotide (to be marketed as Vyleesi) is used on-demand. Bremelanotide is a peptide [...]

By |2019-07-10T12:01:16-04:00July 16th, 2019|General, Sexual Health|Comments Off on In Brief: FDA Approves New Drug to Improve Sexual Desire in Women

New Progestin-Only Contraceptive Approved by the FDA

The Food and Drug Administration has approved a new progestin-only oral contraceptive called Slynd.  This preparation contains the novel progestin drospirenone which is one component of the oral contraceptives (OCs) YaZ and Yasmin.  (These contraceptives [...]

By |2019-06-03T08:42:14-04:00June 3rd, 2019|Contraception, General, Hormone Therapy|Comments Off on New Progestin-Only Contraceptive Approved by the FDA

Medications for Female Sexual Dysfunction: Are They Better than Placebo?

Randomized controlled trials of pharmacologic agents for the treatment of female sexual dysfunction (FSD) have typically shown significant placebo responses.  In a recent meta-analysis, researchers have assessed the magnitude of this effect. The analysis was [...]

By |2020-11-26T08:22:24-04:00July 31st, 2018|General, Sexual Health|Comments Off on Medications for Female Sexual Dysfunction: Are They Better than Placebo?

Hormonal Contraceptives and Risk for Depression and Suicide

Many women have concerns about the side effects of hormonal contraceptives, including oral contraceptives, depot preparations, and hormonal IUDs and vaginal rings.  Potential side effects include bloating, breast tenderness, and weight gain. In addition, some [...]

By |2019-03-15T09:43:31-04:00March 13th, 2018|Depressive Disorders, General|Comments Off on Hormonal Contraceptives and Risk for Depression and Suicide

Use of ADHD Medications Increasing in Women of Reproductive Age

  According to a report published by the CDC in Morbidity and Mortality Weekly Report (MMWR), the use of stimulant medications for the treatment of attention-deficit/hyperactivity disorder (ADHD)  by reproductive-age women is on the rise. [...]

By |2018-01-24T11:21:15-04:00January 24th, 2018|ADHD Medications, General|Comments Off on Use of ADHD Medications Increasing in Women of Reproductive Age

Estrogen Receptor Modulator Raloxifene for Women with Schizophrenia

Several years ago, we reviewed a paper suggesting that estrogen may have beneficial effects for women with schizophrenia.  In this study, women with schizophrenia were treated with estrogen in addition to their antipsychotic medications.  Adjunctive [...]

By |2021-11-04T08:24:19-04:00September 7th, 2017|General, Schizophrenia and Psychotic Disorders|Comments Off on Estrogen Receptor Modulator Raloxifene for Women with Schizophrenia

Pregnancy Termination Does Not Affect Women’s Long-term Mental Health or Well-Being

The US Surgeon General made the recommendation in 1989 that a five-year longitudinal cohort study was necessary to provide data about the health effects of an elective termination on women. To rise to this challenge, [...]

By |2017-01-11T17:57:54-04:00January 12th, 2017|General, Pregnancy Termination|Comments Off on Pregnancy Termination Does Not Affect Women’s Long-term Mental Health or Well-Being
Go to Top